Prospective Sibling Oocyte Study of a New Method to Improve Embryo Development in IVF/ICSI Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mariano Buffone, PhD
- Phone Number: 1314 +54114783 2869
- Email: buffone@fecundis.com
Study Locations
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, 1058
- In Vitro Buenos Aires
-
Buenos Aires, Buenos Aires F.D., Argentina, 1425
- Pregna
-
Buenos Aires, Buenos Aires F.D., Argentina, 1428
- WeFIV
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2282
- Fertya
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Female:
Inclusion Criteria:
- With ovarian reserve of between 8 and 30 antral follicles counting both ovaries
- Treatment planned for embryo transfer at the blastocyst stage
Exclusion Criteria:
- Any diagnosed sexually transmitted infection (STI)
- Diabetes or other metabolic disorders.
- Recurrent pregnancy loss (defined as >2 clinical pregnancies without live birth).
- Previous failures in two or more IVF cycles
Male:
Inclusion Criteria for IVF:
- Age: 20-55 years
- Fresh sample (not cryopreserved )
- Sperm motility (TOTAL) ≥ 40% in spermogram
- Normal sperm morphology (Kruger criteria) ≥ 4% in spermogram
- Sperm count after swim up ≥ 5x10^6
- Treatment planned for embryo transfer at the blastocyst stage
Inclusion Criteria for ICSI:
- Age: 20-55 years
- Fresh sample (not cryopreserved )
- Sperm concentration ≥ 10x10^6 /ml in spermogram
- Sperm motility (TOTAL) ≥ 20% in spermogram
- Normal sperm morphology (Kruger criteria) ≥ 3% in spermogram
- Treatment planned for embryo transfer at the blastocyst stage
Exclusion Criteria:
- Any diagnosed sexually transmitted infection (STI)
- Total failure of in vitro fertilization in previous cycles.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard Sperm Preparation
Sperm samples in the control group will undergo traditional processing in the lab prior to insemination.
|
Standard sperm preparation
|
|
Experimental: HyperSperm
Sperm samples in the experimental group will undergo product-specific processing in the lab prior to insemination.
|
Multi-step sperm preparation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Development rate to blastocysts
Time Frame: Days 5-6 post insemination
|
Total blastocysts / total fertilized oocytes
|
Days 5-6 post insemination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fertilization rate
Time Frame: Day 1 post insemination
|
Total fertilized oocytes (formation of two pronuclei) / total inseminated oocytes
|
Day 1 post insemination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mariano Buffone, PhD, Fecundis Lab SL
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Fecundis_2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.